The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma

Abstract Background BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side effects that can lengthen hospital stays and increase morbidity. Hematological toxicity (e.g. profound and prolonged cytopeni...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Journal of Hematology & Oncology
المؤلفون الرئيسيون:	Kai Rejeski, Doris K. Hansen, Radhika Bansal, Pierre Sesques, Sikander Ailawadhi, Jennifer M. Logue, Eva Bräunlein, David M. Cordas dos Santos, Ciara L. Freeman, Melissa Alsina, Sebastian Theurich, Yucai Wang, Angela M. Krackhardt, Frederick L. Locke, Emmanuel Bachy, Michael D. Jain, Yi Lin, Marion Subklewe
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	BMC 2023-07-01
الموضوعات:	Chimeric antigen receptor BCMA CAR-T Hematological toxicity Cytopenias Multiple myeloma Infections
الوصول للمادة أونلاين:	https://doi.org/10.1186/s13045-023-01465-x